Summary:
Phase 2, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, dose-ranging, dose-finding, parallel-group study to assess efficacy and safety of PF-06865571
Qualified Participants Must:
• Age 18-75
• BMI 25-40
• Body weight must be stable
• diagnosed with fatty liver/NASH
Qualified Participants May Receive:
Compensation up to $2988.00